Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients After Stem Cell Transplant

NCT03560752 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03560752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03560752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients After Stem Cell Transplant
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 20, 2018
Completion date
June 28, 2027
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase cml, bcr-abl1 positive, acute lymphoblastic leukemia in remission, acute myeloid leukemia in remission, chronic lymphocytic leukemia, chronic phase cml, bcr-abl1 positive, cytomegalovirus positive, donor, hematopoietic and lymphoid cell neoplasm, hematopoietic cell transplant recipient, hodgkin lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, myelofibrosis, non-hodgkin lymphoma